Clinical developments of antitumor polymer therapeutics

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Polymer therapeutics are nano-sized, multicomponent constructs used clinically as antitumor agents.
• Nanoparticle-based polymer-conjugated therapeutics offer advantages like prolonged half-life, stability, selectivity, and targeted delivery for cancer treatment.
• Conventional chemotherapy causes severe side effects due to lack of discrimination between cancer and healthy cells.

Purpose of the Study:

• To review current advancements in antitumor polymer therapeutics.
• To highlight polymer-drug conjugates, polymeric micelles, liposomes, and nanoparticles under investigation.
• To address remaining challenges in polymeric drug conjugates.

Main Methods:

• Literature review of polymer therapeutics in cancer treatment.
• Analysis of nanoparticle-based drug delivery systems.
• Discussion of challenges and future scope in the field.

Main Results:

• Polymer therapeutics demonstrate preferential accumulation in tumor sites, reducing systemic toxicity.
• These systems can maintain constant therapeutic drug concentrations over extended periods.
• Various formulations like polymer-drug conjugates, micelles, liposomes, and nanoparticles are under investigation.

Conclusions:

• Polymer therapeutics represent a promising strategy for enhanced cancer treatment delivery.
• Further research is needed to overcome existing challenges in polymeric drug conjugates.
• This field holds significant potential for improving patient outcomes in oncology.